LifeCycle Pharma Increases Share Capital by 150,813 Shares as a Consequence of the Exercise of Employee Warrants

Company Announcement no. 6/2009

To: NASDAQ OMX Copenhagen                             Hørsholm, Denmark, March
25, 2009			 
LifeCycle Pharma Increases Share Capital by 150,813 Shares as a Consequence of
the Exercise of Employee Warrants 

 LifeCycle Pharma A/S (OMX: LCP) has decided to increase its share capital by
nom. 150,813 shares as a consequence of the exercise of warrants. The increase
is executed without any pre-emption rights for the existing shareholders of the
company or others. 

The shares are subscribed in cash as follows: (1) Nom. 27,760 shares are
subscribed against payment of DKK 6,0634 per share of nom. DKK 1. (2) Nom.
123,053 shares are subscribed against payment of DKK 6,4782  per share of nom.
DKK 1. Gross proceeds to the company are DKK 964,929. The increase corresponds
to approx. 0,27 % of the company's share capital after the increase. The new
shares are ordinary bearer shares without any special rights and are freely
transferable negotiable instruments. The new shares shall give rights to
dividends and other rights in relation to the company from the date of the
registration of the capital increase with the Commerce and Companies Agency.
The new shares will be listed on the NASDAQ OMX Copenhagen after registration
with the said agency. The company's current share capital amounts to DKK
56,287,507 shares and will after the capital increase be DKK 56,438,320. The
capital increase is expected to be finalized shortly. 

For more information, please contact:
LifeCycle Pharma A/S
Peter Schøtt Knudsen
Head of Investor Relations
Phone: + 45 2055 3817
Email: PSK@lcpharma.com


About LifeCycle Pharma A/S (LCP)
Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging
specialty pharmaceutical company. Clinical development is the core of LCP's
effort to develop a product portfolio which includes products for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. As a fully integrated company, LCP adapts new
technologies on a fast commercial timetable. LCP's unique, patented delivery
technology, MeltDose®, can improve absorption and bioavailability - at
low-scale up costs - not only for a broad spectrum of drugs already on the
market but also for new chemical entities. LCP has a cholesterol-lowering
product, Fenoglide™, currently on the U.S. market and a diversified near- and
medium-term pipeline with four product candidates in clinical trials and a
number of projects in preclinical development. LCP is listed on the NASDAQ OMX
Copenhagen under the trading symbol (OMX: LCP). 

For further information, please visit www.lcpharma.com.